Imagine a vaccine that acts like a high-definition photograph of a virus, showing your immune system exactly what to fight without needing extra chemical boosters. While many current vaccines wear off quickly, this technology is designed to keep the body protected for years. It focuses on dangerous viruses like Nipah, which currently have no available treatments.
Current vaccines often suffer from fast waning protection, leaving populations vulnerable shortly after vaccination. There are currently no vaccines or treatments available for high-mortality viruses like Nipah.
A portfolio of vaccine candidates, specifically a NiV G protein displayed on cVLP, and approximately 100 antigen constructs for various henipaviruses and filoviruses.
If you are a vaccine manufacturer dealing with the fast waning of protection in current shots — this project developed a cVLP platform that provides long-term protection (>2 years). This allows for the creation of a vaccine portfolio ready for Phase 2&3 development.
If you are a health agency dealing with the risk of high-mortality outbreaks — this project developed a vaccine candidate for Nipah virus that is rapidly acting (within 2 weeks). This ensures medical workers and the public are protected during sudden epidemics.
If you are a CRO dealing with the need for proven vaccine platforms — this project developed a cVLP technology that is clinically proven to generate high-level neutralizing antibodies without adjuvants. It includes a Phase 1/2a clinical study to prove the concept.
Based on available project data, there is no information regarding the cost or pricing of the vaccine candidates.
The project adapts template processes from a COVID-19 vaccine currently in Phase 3, suggesting a path toward industrial scalability, though specific scale metrics are not provided.
Based on available project data, specific IP or licensing terms are not disclosed, but the technology is being developed by a consortium including two SMEs and three universities.
The project aims to test the vaccine within 48 months in a Phase 1/2a clinical study.
It provides a portfolio of vaccine candidates ready for rapid transition to Phase 2&3 development in the event of an outbreak.
The consortium is well-balanced for translation, consisting of 8 partners across 5 countries. With a 25% industry ratio (2 SMEs), the project bridges the gap between academic research (3 universities, 3 research institutes) and commercial application, leveraging existing Phase 3 experience to accelerate the NiV vaccine pipeline.
Contact Kobenhavns Universitet (University of Copenhagen) regarding the VICI-DISEASE project.
Contact us to explore licensing opportunities for the cVLP vaccine platform.
